Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can A New Drug Screen Crack The Code On Myelin Repair?

This article was originally published in Start Up

Executive Summary

A new high-throughput assay developed at the University of California, San Francisco has already identified a generic over-the-counter drug that promotes remyelination. A clinical trial is soon to follow, only the second for myelin repair in multiple sclerosis.

Advertisement

Related Content

With Tecfidera, Biogen Idec Delivers Best MS Product Launch Yet

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092525

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel